Induction of apoptotic cell death by Pharbitis nil extract in HER2-overexpressing MCF-7 cells

Journal of Ethnopharmacology

Volumn 133, Issue 1, 2011, Pages 126-131

  Ju, Ji Hyun ^a   Jeon, Min Jeong ^a   Yang, Wonseok ^a   Lee, Kyung Min ^a   Seo, Hye Sook ^a   Shin, Incheol ^a  

^a Hanyang University   (South Korea)

Author keywords

Akt; Apoptosis; Breast cancer; ERK; HER2; Pharbitis nil

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CYCLIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHARBITIS NIL EXTRACT; PLANT EXTRACT; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IPOMOEA NIL; ONCOGENE NEU; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FAR EAST; FEMALE; HUMANS; IPOMOEA NIL; PHYTOTHERAPY; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2;

IPOMOEA NIL;

EID: 78650680189     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.09.021     Document Type: Article

References (37)

1. J.P. Alao, S.C. Gamble, A.V. Stavropoulou, K.M. Pomeranz, E.W. Lam, R.C. Coombes, and D.M. Vigushin The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines Molecular Cancer 5 2006 7
2. S.S. Bacus, Y. Yarden, M. Oren, D.M. Chin, L. Lyass, C.R. Zelnick, A. Kazarov, W. Toyofuku, J. Gray-Bablin, R.R. Beerli, N.E. Hynes, M. Nikiforov, R. Haffner, A. Gudkov, and K. Keyomarsi Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells Oncogene 12 1996 2535 2547
3. P.L. Bedard, E. de Azambuja, and F. Cardoso Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer Current Cancer Drug Targets 9 2009 148 162
4. S. Bonovas, A. Tsantes, T. Drosos, and N.M. Sitaras Cancer chemoprevention: a summary of the current evidence Anticancer Research 28 2008 1857 1866
5. A.U. Buzdar Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer Annals of Oncology 20 2009 993 999
6. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
7. P. Casalini, L. Botta, and S. Menard Role of p53 in HER2-induced proliferation or apoptosis Journal of Biological Chemistry 276 2001 12449 12453
8. W. Dean-Colomb, and F.J. Esteva HER2-positive breast cancer: herceptin and beyond European Journal of Cancer 44 2008 2806 2812
9. L.C. Dorssers, S. Van der Flier, A. Brinkman, T. van Agthoven, J. Veldscholte, E.M. Berns, J.G. Klijn, L.V. Beex, and J.A. Foekens Tamoxifen resistance in breast cancer: elucidating mechanisms Drugs 61 2001 1721 1733
10. S. Fan, M.L. Smith, D.J. Rivet 2nd, D. Duba, Q. Zhan, K.W. Kohn, A.J. Fornace Jr., and P.M. O'Connor Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline Cancer Research 55 1995 1649 1654
11. S. Germano, and L. O'Driscoll Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine Current Cancer Drug Targets 9 2009 398 418
12. K.H. Kim, S.U. Choi, and K.R. Lee Diterpene glycosides from the seeds of Pharbitis nil Journal of Natural Products 72 2009 1121 1127
13. S.G. Ko, S.H. Koh, C.Y. Jun, C.G. Nam, H.S. Bae, and M.K. Shin Induction of apoptosis by Saussurea lappa and Pharbitis nil on AGS gastric cancer cells Biological & Pharmaceutical Bulletin 27 2004 1604 1610
14. J.C. Koo, S.Y. Lee, H.J. Chun, Y.H. Cheong, J.S. Choi, S. Kawabata, M. Miyagi, S. Tsunasawa, K.S. Ha, D.W. Bae, C.D. Han, B.L. Lee, and M.J. Cho Two hevein homologs isolated from the seed of Pharbitis nil L. exhibit potent antifungal activity Biochima et Biophysica Acta 1382 1998 80 90
15. J.E. Kucab, C. Lee, C.S. Chen, J. Zhu, C.B. Gilks, M. Cheang, D. Huntsman, E. Yorida, J. Emerman, M. Pollak, and S.E. Dunn Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours Breast Cancer Research 7 2005 R796 807
16. A. Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, H.A. Harvey, C. Brady, C.M. Nalin, M. Dugan, W. Carney, and J. Allard Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer Journal of Clinical Oncology 20 2002 1467 1472
17. Z.Z. Liu, Z.Y. Yu, X.N. Ouyang, X.H. Dai, X. Chen, Z.Q. Zhao, W.W. Wang, J. Li, H. Tu, L. Ye, and Y. Yan Effects of Feitai Capsule on quality of life in patients with advanced non-small-cell lung cancer: a randomized controlled trial Zhong Xi Yi Jie He Xue Bao 7 2009 611 615
18. M. Magni, S. Shammah, R. Schiro, W. Mellado, R. Dalla-Favera, and A.M. Gianni Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer Blood 87 1996 1097 1103
19. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 2007 1261 1274
20. S. Menard, S.M. Pupa, M. Campiglio, and E. Tagliabue Biologic and therapeutic role of HER2 in cancer Oncogene 22 2003 6570 6578
21. A. Munshi Resource-sparing and cost-effective strategies in current management of breast cancer Journal of Cancer Research and Therapeutics 5 2009 116 120
22. E.A. Musgrove, and R.L. Sutherland Biological determinants of endocrine resistance in breast cancer Nature Reviews Cancer 9 2009 631 643
23. D.L. Nielsen, M. Andersson, and C. Kamby HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors Cancer Treatment Reviews 35 2009 121 136
24. C. O'Brien, G. Cavet, A. Pandita, X. Hu, L. Haydu, S. Mohan, K. Toy, C.S. Rivers, Z. Modrusan, L.C. Amler, and M.R. Lackner Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer Cancer Research 68 2008 5380 5389
25. X. Pivot, L. Asmar, A.U. Buzdar, V. Valero, and G. Hortobagyi A unified definition of clinical anthracycline resistance breast cancer British Journal of Cancer 82 2000 529 534
26. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
27. M. Schuler, and D.R. Green Mechanisms of p53-dependent apoptosis Biochemical Society Transactions 29 2001 684 688
28. Y. Shen, and E. White p53-dependent apoptosis pathways Advances in Cancer Research 82 2001 55 84
29. I. Shin, and C.L. Arteaga Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells IUBMB Life 58 2006 664 669
30. C.C. Spevak, E.H. Park, A.P. Geballe, J. Pelletier, and M.S. Sachs HER-2 upstream open reading frame effects on the use of downstream initiation codons Biochemical and Biophysical Research Communications 350 2006 834 841
31. T. Stiewe, and B.M. Putzer Role of the p53-homologue p73 in E2F1-induced apoptosis Nature Genetics 26 2000 464 469
32. E. Tokunaga, E. Oki, K. Nishida, T. Koga, A. Egashira, M. Morita, Y. Kakeji, and Y. Maehara Trastuzumab and breast cancer: developments and current status International Journal of Clinical Oncology 11 2006 199 208
33. S.M. Tolaney, and I.E. Krop Mechanisms of trastuzumab resistance in breast cancer Anti-Cancer Agents in Medicinal Chemistry 9 2009 348 355
34. V.G. Vogel Chemoprevention strategies 2006 Current Treatment Options in Oncology 8 2007 74 88
35. W. Yang, J.H. Ju, M.J. Jeon, X. Han, and I. Shin Danshen (Salvia miltiorrhiza) extract inhibits proliferation of breast cancer cells via modulation of Akt activity and p27 level Phytotherapy Research 24 2010 198 204
36. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology 2 2001 127 137
37. Q. Zhan, S. Fan, I. Bae, C. Guillouf, D.A. Liebermann, P.M. O'Connor, and A.J. Fornace Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis Oncogene 9 1994 3743 3751